Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Ascelia Pharma AB (publ)
  6. News
  7. Most relevant
    ACE   SE0010573113

ASCELIA PHARMA AB (PUBL)

(ACE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about ASCELIA PHARMA AB (PUBL)
2021Ascelia Pharma receives FDA acceptance of IND application for Oncoral clinical trial
AQ
2021Ascelia Pharma AB Receives FDA Acceptance of IND Application for Oncoral Clinical Trial
CI
2021Results from Orviglance comparison study to gadolinium presented at RSNA 2021
AQ
2021Ascelia Pharma AB Announces Results from Orviglance comparison study to gadolinium pres..
CI
2021Nomination Committee appointed for AGM 2022 in Ascelia Pharma AB
AQ
2021QUARTERLY REPORT Q3 2021 : Oncoral – entering clinical collaboration
AQ
2021Ascelia Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended ..
CI
2021ASCELIA PHARMA : Food Effect Study with Orviglance successfully completed
AQ
2021Ascelia Pharma AB Completes Food Effect Study with Orviglance Successfully
CI
2021ASCELIA PHARMA : Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the ..
AQ
2021Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the..
CI
2021ASCELIA PHARMA AB(OM : ACE) added to S&P Global BMI Index
CI
2021Certain Ordinary Shares of Ascelia Pharma AB are subject to a Lock-Up Agreement Ending ..
CI
2021QUARTERLY REPORT Q2 2021 : Preparing Oncoral for the next level
AQ
2021Ascelia Pharma AB publ Announces Earnings Results for the Second Quarter Ended June 30,..
CI
2021ASCELIA PHARMA : Covid-19 extends recruitment period of SPARKLE study
AQ
2021Ascelia Pharma AB Announces That the Continued Global Impact of the Covid-19 Pandemic C..
CI
2021ASCELIA PHARMA : Abstract for Orviglance comparison study to gadolinium accepted at the wo..
AQ
2021Ascelia Pharma AB Announces Abstract for Orviglance Comparison Study to Gadolinium Acce..
CI
2021ASCELIA PHARMA : receives conditional FDA acceptance for brand name Orviglance
AQ
2021Ascelia Pharma AB Receives Conditional U.S. Food and Drug Administration Acceptance for..
CI
2021QUARTERLY REPORT Q1 2021 : US office opened in preparation of launch
AQ
2021Ascelia Pharma AB Publ Reports Earnings Results for the First Quarter Ended March 31, 2..
CI
2021ASCELIA PHARMA : Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 20..
AQ
2021ASCELIA PHARMA : Number of shares and votes in Ascelia Pharma AB
AQ
2021ASCELIA PHARMA AB : publishes prospectus regarding admission to trading of newly issued sh..
AQ
2021ASCELIA PHARMA : Bulletin from the extraordinary general meeting in Ascelia Pharma AB
AQ
2021ASCELIA PHARMA : Issue and repurchase of series C shares for share saving program
AQ
2021ASCELIA PHARMA : Notice of annual general meeting in ascelia pharma ab
AQ
2021ASCELIA PHARMA : Number of shares and votes in Ascelia Pharma AB
AQ
2021ASCELIA PHARMA : publishes Annual Report for 2020
AQ
2021ASCELIA PHARMA : Notice of extraordinary general meeting in Ascelia Pharma
AQ
2021ASCELIA PHARMA : has carried out a directed new share issue raising SEK 200 million
AQ
2021ASCELIA PHARMA : intends to carry out a directed new share issue
AQ
2021ASCELIA PHARMA : opens US office in preparation for Mangoral launch
AQ
2021Ascelia Pharma AB Opens US Office in Preparation for Mangoral Launch
CI
2021QUARTERLY REPORT Q4 2020 : Mangoral shows high diagnostic value in new study
AQ
2021Ascelia Pharma AB Reports Earnings Results for the Fourth Quarter of 2020
CI
2021ASCELIA PHARMA : Information regarding transfer of shares in Ascelia Pharma AB from CMC SP..
AQ
2021ASCELIA PHARMA : presents clinical development plan for Oncoral as a novel chemotherapy
AQ
2021Ascelia Pharma AB Presents Clinical Development Plan for Oncoral as a Novel Chemotherap..
CI
2020ASCELIA PHARMA : gets US patent for secondágeneration Mangoral
AQ
2020Ascelia Pharma Gets US Patent for Second Generation Mangoral
CI
2020ASCELIA PHARMA : New study shows Mangoral's lesion visualization as effective as gadoliniu..
AQ
2020Ascelia Pharma AB Announces New Study Shows Mangoral's Lesion Visualization as Effectiv..
CI
2020QUARTERLY REPORT Q3-2020 : Raised market estimate for Mangoral and preparing for market la..
AQ
2020Ascelia Pharma AB Announces Earnings Results for the Third Quarter of 2020
CI
2020ASCELIA PHARMA : EMA confirms Mangoral eligible for the centralized regulatory procedure i..
AQ
2020ASCELIA PHARMA : Upgraded estimate of addressable market for Mangoral to $500-600 million ..
AQ
2020ASCELIA PHARMA : Invitation to Ascelia Pharma's virtual Capital Markets Day
AQ
2020ASCELIA PHARMA : First commercial scale manufacturing of Mangoral
AQ
2020QUARTERLY REPORT Q2-2020 : First participant in the hepatic study
AQ
2020Ascelia Pharma AB Reports Consolidated Earnings Results for the Second Quarter and Firs..
CI
2020ASCELIA PHARMA PUBL : Change in number of shares and votes in Ascelia Pharma AB
AQ
2020ASCELIA PHARMA PUBL : completes a directed new share issue of 4,697,781 shares, raising ap..
AQ
2020Ascelia Pharma AB announced that it has received SEK 98.653401 million in funding from ..
CI
2020VATOR SECURITIES : Ascelia Pharma: A delay. Fundamentals for Mangoral remain unchanged.
AQ
2020ASCELIA PHARMA PUBL : Updated SPARKLE timelines due to Covid-19 impact
AQ
2020Ascelia Pharma AB Announces Updated SPARKLE Timelines Due to COVID-19 Impact
CI
2020INTERIM FINANCIAL REPORT Q1-2020 : First patient enrolled in Phase 3 study SPARKLE
AQ
2020Ascelia Pharma AB Reports Earnings Results for the First Quarter Ended March 2020
CI
2020Ascelia Pharma AB Resolves to Elect Lauren Barnes as New Ordinary Board Member
CI
2020ASCELIA PHARMA PUBL : Bulletin from the Annual General Meeting in Ascelia Pharma AB on 6 M..
AQ
2020ASCELIA PHARMA PUBL : First participant enrolled in the clinical hepatic impairment study ..
AQ
2020Ascelia Pharma AB Announces First Participant Enrolled in it's Clinical Study with Mang..
CI
2020Ascelia Pharma AB Announces Approval of Patent Application for Oncoral in Japan
CI
2020ASCELIA PHARMA PUBL : Patent for Oncoral approved in Japan
AQ
2020ASCELIA PHARMA PUBL : publishes Annual Report for the financial year 2019
AQ
2020ASCELIA PHARMA PUBL : Nomination Committee proposes election of Lauren Barnes to the Board..
AQ
2020ASCELIA PHARMA PUBL : Correction to press release regarding in change in number of shares ..
AQ
2020ASCELIA PHARMA PUBL : Change in number of shares and votes in Ascelia Pharma AB
AQ
2020ASCELIA PHARMA PUBL : Leading Ascelia Pharma through the Covid-19 period
AQ
2020Certain Shares of Ascelia Pharma AB are subject to a Lock-Up Agreement Ending on 13-MAR..
CI
2020ASCELIA PHARMA PUBL : Issue and repurchase of series C shares for share saving program
AQ
2020VATOR SECURITIES : Ascelia Pharma: A rocket roll out is the key to success
AQ
1  2Next
Upcoming event on ASCELIA PHARMA AB (PUBL)